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Objective: Artificial lungs may have a role in supporting patients with end-stage
lung disease as a bridge or alternative to lung transplantation. This investigation was
performed to determine the effect of an artificial lung, perfused by the right ventri-
cle in parallel with the pulmonary circulation, on indices of right ventricular load in
a model of pulmonary hypertension.
Methods: Seven adult male sheep were connected to a low-resistance membrane
oxygenator through conduits anastomosed end to side to the pulmonary artery and
left atrium. Banding of the distal pulmonary artery generated acute pulmonary
hypertension. Data were obtained with and without flow through the device con-
duits. Outcome measures of right ventricular load included hemodynamic parame-
ters, as well as analysis of impedance, power consumption, wave reflections,
cardiac efficiency, and the tension-time index.
Results: The model of pulmonary hypertension increased all indices of right ven-
tricular load and decreased ventricular efficiency. Allowing flow through the artifi-
cial lung significantly reduced mean pulmonary artery pressure, zero harmonic
impedance, right ventricular power consumption, amplitude of reflected waves, and
the tension-time index. Cardiac efficiency was significantly increased.
Conclusions: An artificial lung perfused by the right ventricle and applied in paral-
lel with the pulmonary circulation reduces ventricular load and improves cardiac
efficiency in the setting of pulmonary hypertension. These data suggest that an arti-
ficial lung in this configuration may benefit patients with end-stage lung disease and
pulmonary hypertension with right ventricular strain.
Lung transplantation is the only treatment for most patients with end-stage lung disease. However, although the candidate registry contin-ues to grow, the number of transplants performed has reached aplateau, limited by the finite pool of cadaveric organs.1 Becauseallocation for lungs in the United States is based entirely on waitingtime rather than urgency, the wait-list mortality is exceedingly high.
Furthermore, there is reluctance by many centers to perform transplants in patients
requiring mechanical ventilation.2 For those patients who decompensate while
awaiting the availability of a suitable organ, there are currently no options, illus-
trating the need for new and innovative solutions.
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A pulmonary assist device, or artificial lung, may have a
role in supporting these patients as a bridge or even as an
alternative to transplantation. Such strategies are now rou-
tine with cardiac failure3 and have been explored for liver
failure.4 Although extracorporeal membrane oxygenation
has been successfully used as a short-term support for acute
respiratory failure,5 the inherent complexity and cost are
impractical for use beyond several weeks. Design goals for
an artificial lung should take into account durability for pro-
longed support and simplicity, permitting use on an ambu-
latory basis.
A low-resistance oxygenator can be perfused entirely by
the native cardiac output, obviating the need for a mechan-
ical pump. This straightforward design is perhaps the most
viable strategy because long-term mechanical pumps may
be associated with cellular blood element trauma, may
require frequent close monitoring for evidence of failure,
and would necessarily increase cost.6 Previous studies have
demonstrated the feasibility of a pumpless artificial lung
applied in a variety of configurations.7-11 A lumped param-
eter model defined the theoretical effect on cardiac load for
various applications of an artificial lung perfused by the
right ventricle.12 This simulated computer model predicted
that a device situated in parallel with the pulmonary circu-
lation (Figure 1) would reduce right ventricular power con-
sumption in the setting of elevated pulmonary vascular
resistance. Because many patients on the lung transplant
waiting list have pulmonary hypertension, particularly
those with the highest wait-list mortality,13,14 this applica-
tion may be the most beneficial. We sought to determine, in
an in vivo model of pulmonary hypertension, the effect of
an artificial lung applied in parallel on indices of right ven-
tricular load. Specifically, we were interested in quantifying
and characterizing how this low-resistance but noncompli-
ant oxygenating shunt would influence factors related to
pulsatile flow, such as impedance and reflection waves.
Materials and Methods
Anesthesia and Animal Handling
Seven adult male sheep (59 ± 5 kg) underwent anesthetic induc-
tion with sodium thiopental (7 mg/kg) administered intravenously
and 0.6 mg of buprenorphine hydrochloride administered intra-
muscularly. The animals were intubated with an 11F cuffed endo-
tracheal tube and ventilated with a Narkomed 2 anesthesia
machine (North American Drager, Telford, Pa), maintaining con-
tinuous inhalational anesthesia with isoflurane 0.4% to 4.0%.
Respiratory rate and tidal volumes were adjusted to maintain a
PaCO2 of between 35 and 45 mm Hg and a peak inspiratory pres-
sure of less than 30 cm H2O. Positive end-expiratory pressure of 5
cm H2O was applied continuously. Animals received humane care
in compliance with the National Society for Medical Research, as
well as the Institute of Laboratory Animal Resources. The
University of Michigan Committee on the Use and Care of
Animals (protocol No. 7239) approved all experiments.
Instrumentation
With the animal supine, the right femoral artery was exposed. An
arterial catheter was inserted and connected to a fluid-coupled
strain-gauge pressure transducer (Abbott Critical Care Systems,
Chicago, Ill), and the resulting arterial pressure signal was dis-
played continuously (Marquette Electronics, Milwaukee, Wis).
A muscle-sparing left anterolateral thoracotomy in the fourth
intercostal space was performed, resecting a portion of the fifth rib
for exposure. The pericardium was incised, and the pulmonary
artery (PA) was isolated from the pulmonic valve to the bifurca-
tion. A side-mounted pressure-sensing micromanometer (Millar
Figure 1. Parallel application of the artificial lung involves sharing
right ventricular blood flow with the native lungs. The quantity of
diverted blood flow is related to the comparative resistances of
the artificial and native lungs.
Figure 2. The total artificial lung is a low-resistance oxygenator.
Pressure drop in vitro with water is approximately 2.5 mm Hg,
with 5 L/min flow.
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Instruments, Inc, Houston, Tex) was inserted into the proximal PA
immediately distal to the valve, and the PA pressure (PPA) signal
was displayed continuously. An ultrasonic flow probe (Transonic
24A159; Transonic Systems, Inc, Ithaca, NY) was placed around
the proximal PA to measure instantaneous PA flow (QPA) and
mean PA flow (cardiac output [CO]) with a flowmeter (Transonic
T106). The micromanometer and flow probe were situated such
that PPA and QPA were sampled from the same location. A catheter
was placed in the left superior pulmonary vein and connected to a
fluid-coupled strain-gauge pressure transducer for continuous left
atrial pressure measurement.
Artificial Lung and Acute Pulmonary Hypertension
Inflow and outflow conduits for the artificial lung consisted of 16-
mm Hemashield vascular grafts (Boston Scientific, Natick, Mass)
solvent bonded to 5⁄8-inch polyvinyl chloride tubing. The grafts
were preclotted, and the animal was anticoagulated with 100
IU/kg intravenous sodium heparin. The inflow conduit was anas-
tomosed end to side to the PA, distal to the flow probe and micro-
manometer. The outflow conduit was anastomosed to the left atrial
appendage. The artificial lung (Michigan Critical Care
Consultants, Ann Arbor, Mich) is a radial flow oxygenator con-
taining microporous hollow fibers with a surface area of 2.25 m2
as the gas-exchange substrate (Figure 2). The polypropylene fibers
(Celgard Inc, Charlotte, NC) have an external diameter of 300 µm,
a pore size of 0.03 µm, and a porosity of 40%. Bench-top testing
of the artificial lung demonstrates a rated flow of 9.0 L/min and
steady flow resistance of 0.5 Wood units in water. The device was
primed with approximately 280 mL heparinized saline solution
and connected to the conduits. Once de-airing was complete, the
conduit clamps were removed to establish flow. An ultrasonic flow
probe (Transonic H13X6) was placed around the inflow conduit
tubing and connected to a flowmeter (Transonic HT110). Oxygen
sweep gas flow was adjusted to maintain a PaCO2 of between 35
and 45 mm Hg. Anastomotic patency and hemostasis were con-
firmed, and the conduits were reclamped to restore the native pul-
monary circulation. A flow occluder was then placed around the
distal PA near the bifurcation for generation of acute pulmonary
hypertension. The occluder was gradually inflated until mean PPA
was approximately twice baseline values, not allowing CO to fall
below 3.5 L/min.
Data Acquisition
Data were collected at a sampling frequency of 300 Hz through
a 6-channel circuit board and Labview software (National
Instruments, Austin, Tex) and stored on a personal computer
(Apple Computers, Cupertino, Calif). Three conditions were
evaluated for each animal: (1) baseline (before device applica-
tion); (2) in the setting of acute pulmonary hypertension, with
the artificial lung conduits clamped; and (3) in the setting of
acute pulmonary hypertension, with flow through the artificial
lung. Data were collected for 30 continuous seconds after equil-
ibration had been reached, which was determined by stable PPA,
arterial pressure signal, CO, PaCO2, and oxygen saturation val-
ues. Data were then analyzed on a personal computer (Dell
Computer, Austin, Tex).
Outcomes Analysis
Impedance is the resistance to pulsatile flow and best characterizes
cardiac load.15 Fourier analysis was performed on PPA and QPA,
TABLE 1. Indices of cardiac load and function during baseline conditions and in the setting of acute pulmonary hyperten-
sion, with and without flow through the artificial lung
P value,
PH: artificial
lung clamped vs
PH: artificial PH: artificial PH: artificial
Baseline lung clamped lung open lung open Change (%)
mPAo (mm Hg) 91.7 ± 4.2 53.9 ± 3.1* 73.4 ± 5.4 .008 +36
CO (L/min) 5.8 ± 0.9 4.7 ± 0.4 4.7 ± 0.5 .9 +0
mPpa (mm Hg) 14.8 ± 1.0 28.5 ± 0.7* 15.5 ± 0.7 <.001 –46
Z0 (Wood units) 2.8 ± 0.3 6.3 ± 0.5* 3.5 ± 0.6 <.001 –44
Z1 (Wood units) 0.39 ± 0.03 2.95 ± 0.25* 2.3 ± 0.24 .14 –22
Zc (Wood units) 0.56 ± 0.05 1.93 ± 0.18* 1.4 ± 0.19 .09 –27
Pb (mm Hg) 0.50 ± 0.12 1.35 ± 0.15 0.93 ± 0.11 .02 –31
Wt (mW) 234.9 ± 39.2 380.7 ± 39.5* 231.5 ± 37.8 <.001 –39
CO/Wt (L/J) 25.4 ± 1.3 12.6 ± 0.4* 21.0 ± 1.2 <.001 +67
Wm (mW) 193.1 ± 32.1 298.7 ± 25.8* 158.9 ± 23.4 <.001 –47
Wosc (mW) 41.8 ± 8.0 82.0 ± 17.8* 72.6 ± 18.4 .35 –11
TTI (mm Hg – s/min) 483.5 ± 42.7 1184.6 ± 52.6* 708.2 ± 42.0 <.001 –40
Values are expressed as means ± SE. PH, Pulmonary hypertension; mPAo, mean systemic arterial pressure; mPPA, mean pulmonary arterial pressure;
Z0, zero harmonic; Pb, amplitude of the reflected pressure wave; Wt, total hydraulic power; CO/Wt, ventricular efficiency; Wm, steady hydraulic power;
Wosc, oscillatory hydraulic power; TTI, tension-time index.
*Denotes P < .05 versus baseline conditions.
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breaking down the waveforms into their respective harmonics with
available software (MathWorks, Natick, Mass). Impedance was
calculated by dividing the amplitudes of PPA and QPA at each har-
monic. Resistance is defined by the impedance at the zero har-
monic, and low-frequency impedance is defined by the impedance
at the first harmonic (Z1). Characteristic impedance (Zc), or
impedance in the absence of wave reflections, can be estimated by
the average impedance between 2 and 12 Hz.16 Signal noise gen-
eration was determined by measuring the oscillations in vitro dur-
ing steady state. Harmonics in which pressure and flow amplitudes
Figure 4. Characteristic impedance (Zc) in the setting of acute pulmonary hypertension (PH) with and without flow
through the artificial lung. The thick black line represents the mean value.
Figure 3. Low-frequency impedance (Z1) in the setting of acute pulmonary hypertension (PH) with and without flow
through the artificial lung. The thick black line represents the mean value.
1098 The Journal of Thoracic and Cardiovascular Surgery • December 2001
General Thoracic Surgery Haft et al
ED
ITO
RIA
L
CH
D
G
TS
A
CD
ET
CSP
TX
exceeded the in vitro–determined noise magnitudes were excluded
from calculations.
When there is a change in the physical properties of a conduit
carrying pulsatile flow, pressure waves are reflected backward,
increasing cardiac load. A measured pressure wave is therefore the
sum of its forward and backward components. The backward com-
ponent can be determined with the following formula:
Pb = (PPA – ZcQPA)/2,
where Pb is the backward pressure wave.17 The amplitude of Pb
oscillations was determined by Fourier analysis.
Total right-side heart power (Wt), or energy consumed, was
determined by the time-averaged integral of the product of PPA and
QPA. Mean power (Wm) is the energy expended to produce for-
ward flow and is the product of mean PPA and CO. Oscillatory
power represents energy wasted in oscillations without generating
flow and can be determined by Wt – Wm.15 CO/Wt, or flow gener-
ated per unit of energy consumed, is an index of ventricular effi-
ciency.16 The tension-time index is a correlate of myocardial
oxygen consumption and was determined by the product of the
PPA integral during systole and the heart rate.18
Statistical Analysis
Data are expressed as means ± SE. Statistical analyses were per-
formed with a Student 2-tailed paired t test.
Results
All animals tolerated instrumentation and application of the
artificial lung, as described. During the generation of acute
pulmonary hypertension, all animals had systemic hypoten-
sion, but CO did not fall to less than 3.5 L/min. The model
of pulmonary hypertension increased all measured indices
of right ventricular load, as shown in Table 1, with an
approximate 50% reduction in ventricular efficiency.
Unclamping of the conduits resulted in diverting a por-
tion of the right ventricular output through the artificial
lung. The quantity of blood diverted through the device
ranged from 2.5 to 4.6 L/min or 71% ± 5% of the total right
ventricular output. Oxyhemoglobin saturation of the blood
exiting the device was always 100%. Significant reductions
in mean PPA, zero harmonic, tension-time index, Wt, Wm,
and Pb values were observed, with an increase in ventricu-
lar efficiency (Table 1). Although not achieving statistical
significance, Z1 and Zc trended downward (Figures 3 and
4). Input impedance spectra for all 3 conditions are depicted
in Figure 5.
Discussion
Artificial organs have prolonged survival and improved
quality of life for patients with a variety of types of organ
failure. Artificial lungs may provide such a benefit to those
patients with end-stage lung disease, either as a bridge or as
an alternative to lung transplantation. A device designed for
this purpose must be capable of satisfying the gas-exchange
requirements of these patients for a prolonged period, with
minimal stress on other organ systems. Because experience
with ventricular assist devices has demonstrated improved
outcomes for patients successfully managed on an ambula-
Figure 5. Mean values of pulmonary input impedance spectra at baseline and in the setting of acute pulmonary hyper-
tension (PH) with and without flow through the artificial lung. Error bars reflect SE.
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tory basis,6 an artificial lung should be uncomplicated
enough to allow similar patient independence. A strategy in
which a pumpless oxygenator is used as an artificial lung,
as demonstrated in this study, would simplify the design,
which may facilitate ambulatory use, minimize blood
trauma, and diminish cost.
The native cardiac output can perfuse a low-resistance
oxygenator through several theoretical configurations. An
arteriovenous approach, in which arterial blood is shunted
through the device, takes advantage of the more powerful
and tolerant left ventricle; however, it is limited primarily to
carbon dioxide removal.10,11 In contrast, venous blood,
because of its lower oxyhemoglobin saturation, must be
used to optimize oxygen transfer. A pulmonary replace-
ment, in which the entire right ventricular output is diverted
from the main PA to the artificial lung and returned directly
into the left atrium, may induce cardiac failure or dysfunc-
tion if the resistance and compliance of the artificial lung
differs significantly from that of the native lung.12 In addi-
tion, total elimination of pulmonary blood flow may exac-
erbate lung failure by causing ischemia or thrombosis.9
As an alternative to pulmonary replacement, an artificial
lung can be perfused by the right ventricle either in series or
in parallel with the native lungs. An in-series approach
would divert the entire cardiac output through the device
but return the oxygenated blood back into the distal PA,
therefore preserving native pulmonary blood flow. This
configuration also allows the lungs to serve as an embolic
trap for microthrombi. However, we have previously shown
that the added resistance frequently overloads an untrained
and fragile right ventricle.8
Parallel application involves shunting a portion of the
cardiac output through the device, with return of flow
directed into the left atrium. The comparative resistance of
the artificial and native lungs would determine the quantity
of diverted blood flow. There are several drawbacks to the
parallel approach. Because venous blood flow is shared
between the artificial and native lungs, oxygen delivery by
the device is dependent on the quantity of shunted flow. In
addition, outflow is directed into the left atrium, permitting
thrombus or air emanating from the device to enter the sys-
temic circulation. However, the distinct advantage of the
parallel approach is the potential unloading of the right ven-
tricle, particularly in the setting of pulmonary hypertension.
This study quantified and characterized the magnitude of
right ventricular unloading by an artificial lung applied in
parallel in a model of pulmonary hypertension. As
expected, parallel application greatly reduced indices of
ventricular load associated with steady or constant flow,
such as mean PPA, resistance, and Wm, often by as much as
50%. If these reductions could be extrapolated to patients
with primary pulmonary hypertension, a 50% reduction in
PPA is equivalent to the best therapies currently available.19
Marked improvements in the tension-time index, ventricu-
lar efficiency, and total power consumption further illustrate
the significant benefit to the right ventricle.
The artificial lung used in this study, although extremely
low in resistance, is without compliance. This rigidity may
impede pulsatile flow and generate pressure-wave reflec-
tions. However, this study demonstrated reduced amplitudes
of pressure-wave reflections and decreased impedance at
every harmonic (Figure 5). Low-frequency impedance, mea-
sured at the first harmonic, may have particular physiologic
importance because the first harmonic contains the majority
of the pulsatile flow.20 There appeared to be a reduction in
low-frequency impedance, although this did not achieve sta-
tistical significance (Figure 3).
Characteristic impedance is defined by impedance in the
absence of wave reflections and can be used as a measure of
vascular compliance or arterial stiffness.15 Interestingly,
parallel application of the noncompliant artificial lung pro-
duced a trend toward reduction in Zc (Figure 4). The mech-
anism of this likely involves changing the properties of the
proximal pulmonary tree. As vessels become increasingly
distended, their compliance decreases. Decompression
through the artificial lung decreases PPA and therefore
reduces PA distension. Perhaps reevaluation of this applica-
tion of the artificial lung in a model of pulmonary hyper-
tension that produces an even greater increase in PPA may
enhance changes in Zc.
The gas-exchange efficiency of the artificial lung used in
this study has been previously described.7 Oxygen transfer
is limited only by blood-flow rate and hemoglobin concen-
tration. Because blood flow is shared between the artificial
and native circulations, the device will not satisfy the entire
oxygenation requirements. However, this study demon-
strated, in a model with modest elevation in pulmonary vas-
cular resistance, that the majority of venous blood is
shunted through the artificial lung. Assuming a hemoglobin
concentration of 14 mg/dL and a mixed venous oxyhemo-
globin saturation of 75%, this translates into an oxygen
delivery between 120 and 220 mL/min.
The model of pulmonary hypertension used in this study
does not accurately reflect the hydraulic load seen in
patients with pulmonary hypertension. Others have shown
that PA banding produces an impedance spectra very dis-
similar to that seen in microembolic or primary pulmonary
hypertension.21,22 The significant elevation in Z1 and Pb
seen in our model may explain why all of the animals had
systemic hypotension with only mild elevation of PPA.
Comparison with other known animal models of pulmonary
hypertension may better characterize the potential effect of
a parallel application of the artificial lung in patients with
pulmonary hypertension.
In summary, this study evaluated the hemodynamic ben-
efit to right ventricular load of an artificial lung applied in
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parallel with the pulmonary circulation. Marked reductions
in Wt requirements and improvements in efficiency were
seen in the setting of acute pulmonary hypertension and
attributed to reductions in resistance and pressure-wave
reflections and possibly increased compliance. In addition,
in this model with relatively mild elevation in PPA, approx-
imately two thirds of venous blood flow is passively
shunted through the artificial lung, thereby supplying the
majority of the gas exchange necessary in these animals.
Further testing in more clinically relevant models of pul-
monary hypertension will be enlightening; however, these
preliminary data suggest the potential of an artificial lung in
unloading the strained right ventricle.
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